文献速递胃肠动力与功能性疾病

质子泵抑制剂降低功能性消化不良患者十二指肠嗜酸性粒细胞、肥大细胞及通透性

Proton Pump Inhibitors Reduce Duodenal Eosinophilia, Mast Cells, and Permeability in Patients With Functional Dyspepsia.
PubMed 文献 · Gastroenterology · 2020-12-18

一项前瞻性干预研究纳入30名健康志愿者、27例功能性消化不良(FD)起始治疗患者和18例PPI难治性FD停药患者,评估泮托拉唑40mg每日一次治疗4周前后十二指肠及全身改变。FD患者症状及十二指肠嗜酸性粒细胞、肥大细胞和细胞旁通路显著高于健康志愿者,PPI治疗后降低;健康志愿者用药后免疫细胞和通透性反而增加。

要点

  • FD患者十二指肠嗜酸性粒细胞、肥大细胞及细胞旁通路高于健康志愿者,PPI治疗可降低这些指标。
  • 健康志愿者使用PPI后十二指肠免疫细胞和通透性增加,提示管腔因素(如胆汁盐)可能参与。
  • 消化不良症状与嗜酸性粒细胞相关,PPI降低嗜酸性粒细胞可能是其治疗FD的机制之一。

核心结论

  • 首次前瞻性证据表明PPI通过降低十二指肠嗜酸性粒细胞发挥治疗FD的作用,健康志愿者中的差异效应提示管腔改变的作用。

研究设计与样本

  • 前瞻性干预研究,纳入30名健康志愿者、27例FD起始治疗患者和18例PPI难治性FD停药患者;FD起始组和健康志愿者接受泮托拉唑40mg每日一次治疗4周,FD停药组在停用PPI前及停药8周后评估。

主要发现

  • FD起始组症状及十二指肠嗜酸性粒细胞、肥大细胞(均P < .0001)和细胞旁通路(P = .02)显著高于健康志愿者,PPI治疗后降低。
  • FD停药组停用PPI后症状和十二指肠免疫细胞也降低。
  • 健康志愿者使用PPI后免疫细胞和通透性增加。
  • 消化不良症状在PPI治疗前和治疗期间与嗜酸性粒细胞相关;健康志愿者使用PPI后嗜酸性粒细胞和通透性增加与胆汁盐变化相关。

临床怎么用

  • PPI可能通过降低十二指肠嗜酸性粒细胞改善FD症状,支持其作为FD一线治疗的部分机制。
  • 健康志愿者使用PPI后十二指肠免疫细胞和通透性增加,提示需关注PPI对非FD人群的潜在肠道效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Despite the growing recognition of duodenal alterations in the pathophysiology of functional dyspepsia (FD), the effect and mechanism of proton pump inhibitors (PPIs) or first-line therapy remain unclear. We studied duodenal and systemic alterations in relation to PPI therapy in patients with FD and healthy volunteers (HVs). METHODS: We performed a prospective interventional study assessing symptoms (Patient Assessment of Gastrointestinal Symptom Severity Index), duodenal alterations, and systemic factors in patients with FD ("FD-starters") and HVs before and after PPI therapy (pantoprazole 40 mg once daily for 4 weeks). Duodenal mucosal eosinophils, mast cells and permeability were quantified. Luminal pH and bile salts were determined in duodenal aspirates. Procedures were also performed in PPI-refractory patients with FD ("FD-stoppers") before and 8 weeks after PPI withdrawal. Between- and within-group changes from baseline and associations with duodenal or systemic factors were analyzed using linear mixed models. RESULTS: The study was completed by 30 HV, 27 FD-starters, and 18 FD-stoppers. Symptoms and duodenal eosinophils, mast cells (all, P < .0001), and paracellular passage (P = .02) were significantly higher in FD-starters vs HVs and reduced with PPI therapy. Symptoms and duodenal immune cells also decreased in FD-stoppers off PPIs. In contrast, immune cells and permeability increased in HVs on PPIs. Dyspeptic symptoms correlated with eosinophils before and during PPI therapy, and increased eosinophils and permeability in HVs on PPIs were associated with changes in bile salts. CONCLUSIONS: We provide the first prospective evidence for eosinophil-reducing effects as a therapeutic mechanism of PPIs in FD, with differential effects in HVs pointing to a role of luminal changes. ClinicalTrials.gov, Number: NCT03545243.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Wauters L, Ceulemans M, Frings D, et al. Proton Pump Inhibitors Reduce Duodenal Eosinophilia, Mast Cells, and Permeability in Patients With Functional Dyspepsia. Gastroenterology. 2020. PMID: 33346007. doi:10.1053/j.gastro.2020.12.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。